SSSuwitchaya Sirimanakul

Suwitchaya Sirimanakul

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Suwitchaya Sirimanakul has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Identification of a Nanobody Specific to a Heart Failure Biomarker, B-Type Natriuretic Peptide, from a Synthetic Library Using a Combination of Yeast Surface Display and FLI-TRAP Methods

    by Warisara Kasemsukwimol, Apisitt Thaiprayoon, Nonth Submunkongtawee, Suwitchaya Sirimanakul, Kwanpet Intasurat, Dujduan Waraho-Zhmayev

  • Open Access

    A Simple and Cost-Effective Electrochemical Assay for Heart Failure Prognosis Using Soluble Suppression of Tumorigenicity 2-Specific Nanobodies

    by Suwitchaya Sirimanakul, Joseph D. Hurley, Nakarin Vutipow, Fabien Loison, Anongnard Kasorn, Lueacha Tabtimmai, Pinpunya Riangrungroj, Jeerapond Leelawattanachai, Teetouch Ananwattanasuk, Napachanok Swainson, et al.

    Heart failure (HF) is a major global health concern, particularly in low- and middle-income countries where it is often underdiagnosed. Prognostic testing plays a crucial role in guiding treatment and monitoring disease progression. In this study, we developed an electrochemical assay-based prognostic kit for HF detection targeting soluble suppression of tumorigenicity 2 (sST2). This biomarker offers superior prognostic value compared to traditional methods as it remains stable regardless of patient demographics, including age, sex, obesity, and renal status. To reduce production costs and complexity of the test kit, single-domain antibody fragments (nanobodies) were used in place of conventional antibodies, and an electrochemical platform was used instead of ELISA. We obtained 19 candidate nanobodies from screening a naïve, fully synthetic yeast-display nanobody (Nb) library, and four of these (Nb1, Nb2, Nb5, and Nb13) were prioritized for further study on the basis of high affinity and low polyreactivity. Of these, Nb2 and Nb5 enabled sensitive electrochemical detection of sST2 with limits of detection of 3.37 and 3.00 ng/mL, respectively, in PBS buffer. Further validation using patient serum samples with the Nb5-based platform achieved quantitative detection of sST2 across a predilution concentration range from 0.75 to 93.09 ng/mL, facilitated by sample dilution to mitigate matrix effects and surface saturation. Both nanobodies exhibited high target specificity, with no observed cross-reactivity to other HF biomarkers or serum components. This novel prognostic tool can be produced and performed at low cost, providing a new option for heart failure diagnosis and treatment planning, particularly in low- and middle-income countries, where cost is a major cause of underdiagnosis.

  • Open Access

    Comparative Analysis of the CadF Protein as a Broad-Spectrum Vaccine Target in Four Campylobacter Species

    by Suwitchaya Sirimanakul, Nonth Submankongtawee, Pirada Kanchanapun, Nitichort Supadirek, Sirapat Oyadomari, Duangthip Moonmangmee, Piyaporn Waranusantigul, Dujduan Waraho-Zhamayev

  • Open Access

    Redirecting a Broad-Spectrum Nanobody Against the Receptor-Binding Domain of SARS-CoV-2 to Target Omicron Variants

    by Kwanpet Intasurat, Nonth Submunkongtawee, Phoomintara Longsompurana, Apisitt Thaiprayoon, Warisara Kasemsukwimol, Suwitchaya Sirimanakul, Siriphan Boonsilp, Supaphron Seetaha, Kiattawee Choowongkomon, Dujduan Waraho-Zhmayev

    The urgent need for an effective COVID-19 therapy has propelled the exploration of innovative strategies to combat the fast-mutating SARS-CoV-2 virus. This study attempted to develop nanobodies (Nbs) against the SARS-CoV-2 Omicron variants by redirecting the 1.29 neutralizing Nb, a receptor-binding domain (RBD)-specific Nb that can protect against various SARS-CoV-2 variants other than Omicron, to target SARS-CoV-2 Omicron subvariant BA.5, the variant used for the development of the bivalent vaccine. Error-prone libraries of the 1.29 Nb were constructed. Following two rounds of selection using the functional ligand-binding identification by Tat-based recognition of associating proteins (FLI-TRAP) technique, we rapidly identified two Nbs, namely, C11 and K9, that could target the RBD of the Omicron subvariant BA.5, XBB.1.5, and XBB.1.16 subvariants. Molecular docking provided insights into how these Nbs interact with the RBD of the BA.5 and JN.1 variants. The application of directed evolution via utilization of error-prone PCR and the synthetic E. coli applied in the FLI-TRAP selection method may be a powerful tool for facilitating simple, fast and economical selection to redirect existing antibodies and to generate antibody fragments to target proteins susceptible to autonomous mutation, not only for viral infection but also other diseases, such as cancer.